Valuation: AbbVie

Market Cap 465B 399B 374B 342B 645B 44,310B 648B 4,429B 1,716B 22,354B 1,744B 1,706B 74,040B P/E 2026 *
33.6x
P/E 2027 * 24.8x
Enterprise Value 525B 451B 423B 386B 729B 50,080B 733B 5,006B 1,940B 25,265B 1,971B 1,929B 83,680B EV / Sales 2026 *
7.77x
EV / Sales 2027 * 7.02x
Free-Float
95.71%
Yield 2026 *
2.61%
Yield 2027 * 2.74%
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 69 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 470B
-3.59%-7.10%+61.60%+114.83% 1,100B
-1.15%-1.25%+52.98%+62.41% 658B
-1.09%-1.15%+26.18%+79.22% 470B
-1.47%+0.24%+42.09%+42.09% 372B
-0.90%+0.05%+25.57%+41.75% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.43%-0.46%+52.06%+71.75% 239B
-0.93%+1.84%-13.11%-52.28% 213B
-0.46%+0.33%+29.05%+92.67% 184B
Average -2.00%+0.17%+31.05%+51.74% 422.54B
Weighted average by Cap. -2.51%-1.58%+40.53%+68.24%

Financials

2026 *2027 *
Net sales 67.58B 58.01B 54.45B 49.73B 93.85B 6,446B 94.3B 644B 250B 3,252B 254B 248B 10,771B 73.52B 63.1B 59.23B 54.09B 102B 7,012B 103B 701B 272B 3,538B 276B 270B 11,717B
Net income 13.86B 11.9B 11.17B 10.2B 19.25B 1,322B 19.34B 132B 51.21B 667B 52.05B 50.92B 2,209B 18.91B 16.23B 15.24B 13.92B 26.26B 1,804B 26.39B 180B 69.88B 910B 71.02B 69.47B 3,014B
Net Debt 60.49B 51.92B 48.73B 44.51B 84B 5,769B 84.4B 577B 223B 2,911B 227B 222B 9,640B 51.66B 44.34B 41.62B 38.01B 71.74B 4,927B 72.08B 493B 191B 2,486B 194B 190B 8,233B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA